MedTrace Logo

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

NCT00574496 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, mycophenolate mofetil, and methotrexate before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well combination chemotherapy followed by donor stem cell transplant works in treating patients with relapsed or high-risk primary refractory Hodgkin lymphoma.

Conditions

Interventions

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

gemcitabine hydrochloride

DRUG

ifosfamide

DRUG

mechlorethamine hydrochloride

DRUG

melphalan

DRUG

methotrexate

DRUG

mycophenolate mofetil

DRUG

prednisone

DRUG

procarbazine hydrochloride

DRUG

vincristine sulfate

DRUG

vinorelbine tartrate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

RADIATION

total-body irradiation

Sponsors & Collaborators

Principal Investigators

  • Miguel-Angel Perales, MD · Memorial Sloan Kettering Cancer Center

  • Juliet Barker, MBBS · Memorial Sloan Kettering Cancer Center

  • Tanya Trippett, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-13
Primary Completion
2022-08-02
Completion
2022-08-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574496 on ClinicalTrials.gov